COMPANY IN BRIEF
Phoenix Solutions AS is a Norwegian, innovative start-up biotech company. The company is focused on the development of a technology platform for ultrasound mediated, targeted delivery of drug therapies - Acoustic Cluster Therapy - ACT. (tm). The concept is based on a microparticle formulation system for i.v. administration, which is activated in-vivo by diagnostic ultrasound to provide enhanced uptake and distribution of drugs in target tissue. The technology provides a method for efficient and targeted delivery of drugs such as chemotherapeutics, hence enhancing efficacy, whilst minimising general systemic exposure and resulting side effects.
Phoenix Solution was established as a spin out of technology and senior scientists from GE Healthcare. The company currently operates from GE`s Oslo site with state-of -the art lab facilities and commercial scale manufacturing capability.
Phoenix Solutions develops a platform concept enhancing the therapeutic index and thus clinical utility of a wide range of drugs, from small molecules to nanodrugs. We aim to partner with drug companies in need of our IP protected technology.
Preliminary preclinical studies have shown that ACT™ treatment can induce up to a 10-fold reduction in the growth rate of prostate and pancreatic tumours vs. drug alone (download our Company Flyer for details). Mechanistic studies have shown that ACT™ treatment can increase tumour specific uptake of co-injected molecules as much as 2-300% and that the concept can be applied for controlled opening of the Blood Brain Barrier. Further optimisation is expected to increase effect levels significantly.
The phoenix hope, can wing her way through the desert skies, and still defying fortune's spite; revive from ashes and rise. - Miguel De Cervantes.